Corpus overview


MeSH Disease

Human Phenotype


    displaying 1 - 4 records in total 4
    records per page

    Clinical and pathological findings of SARS-CoV-2 infection MESHD and concurrent IgA nephropathy HP nephropathy MESHD: A case report

    Authors: Liu Liu

    doi:10.21203/ Date: 2020-06-14 Source: ResearchSquare

    Background: Since the Coronavirus Disease MESHD 2019 (COVID-19) outbreak, there is limited data on the clinical characteristics, treatment strategies and prognosis of COVID-19 in patients with concurrent renal disease MESHD. The kidney is believed to have a predisposition for COVID-19 due to its abundant angiotensin-converting enzyme 2 (ACE2) expression, which acts as a cell entry receptor for the severe acute respiratory syndrome coronavirus 2 MESHD (SARS-CoV-2). Recent postmortem investigations reveal renal involvement in COVID-19, and case reports describe collapsing glomerulopathy HP glomerulopathy MESHD in African American patients with COVID-19. However, there is limited data regarding IgA nephropathy HP nephropathy MESHD in the setting of COVID-19.Case presentation: In the present case, we report a 65-year old Chinese woman who presented with macroscopic hematuria HP hematuria MESHD, worsening proteinuria HP proteinuria MESHD and decreased renal function MESHD after COVID-19 infection MESHD. She received a renal biopsy during COVID-19 infection MESHD. The renal biopsy revealed IgA nephropathy MESHD nephropathy HP without any evidence for SARS-Cov-2. The findings suggest that the renal abnormalities MESHD were a consequence of exacerbation of this patient’s underlying glomerular disease MESHD after COVID-19 infection MESHD. After a regimen of 3-day course of glucocorticoid and angiotensin II receptor blocker therapy, the patient recovered and remained stable upon follow-up. Conclusions: It is important to consider the underlying glomerular disease MESHD exacerbation rather than virus induced injury MESHD when dealing with renal abnormalities MESHD in patients with COVID-19.

    Characterisation of Acute Kidney Injury HP Acute Kidney Injury MESHD in Critically Ill Patients with Severe Coronavirus Disease MESHD-2019 (COVID-19)

    Authors: Sebastien RUBIN; Arthur Orieux; Renaud Prevel; Antoine Garric; Marie-Lise Bats; Sandrine Dabernat; Fabrice Camou; Olivier Guisset; Nahema Issa; Gaelle Mourissoux; Antoine Dewitte; Olivier Joannes-boyau; Catherine Fleureau; Hadrien Roze; Cedric Carrie; Laurent Petit; Benjamin Clouzeau; Charline Sazio; Hoang-Nam Bui; Odile Pillet; Claire Rigothier; Frederic Vargas; Christian Combe; Didier Gruson; Alexandre Boyer

    doi:10.1101/2020.05.06.20069872 Date: 2020-05-10 Source: medRxiv

    Background: COVID19-associated acute kidney injury HP kidney injury MESHD frequency, severity and characterisation in critically ill MESHD patients has not been reported. Methods: Single-center cohort performed from March 3, 2020, to April 14, 2020 in 4 intensive care units in Bordeaux University Hospital, France. All patients with COVID19 and pulmonary severity criteria were included. AKI was defined using KDIGO criteria. A systematic urinary analysis was performed. The incidence, severity, clinical presentation, biological characterisation (transient vs. persistent acute kidney injury HP acute kidney injury MESHD; proteinuria HP proteinuria MESHD, hematuria HP hematuria MESHD and glycosuria HP glycosuria MESHD), and short-term outcomes was evaluated. Results: 71 patients were included, with basal serum SERO creatinine of 69 +/- 21 micromol/L. At admission, AKI was present in 8/71 (11%) patients. Median follow-up was 17 [12-23] days. AKI developed in a total of 57/71 (80%) patients with 35% Stage 1, 35% Stage 2, and 30% Stage 3 acute kidney injury HP kidney injury MESHD; 10/57 (18%) required renal replacement therapy. Transient AKI was present in only 4/55 (7%) patients and persistent AKI was observed in 51/55 (93%). Patients with persistent AKI developed a median urine protein/creatinine of 82 [54-140] (mg/mmol) with an albuminuria HP albuminuria MESHD/ proteinuria HP proteinuria MESHD ratio of 0.23 +/- 20 indicating predominant tubulo-interstitial injury. Only 2 (4%) patients had glycosuria HP glycosuria MESHD. At Day 7 onset of after AKI, six (11%) patients remained dependent on renal replacement therapy, nine (16%) had SCr > 200 micromol/L, and four (7%) died. Day 7 and day 14 renal recovery occurred in 28% and 52 % respectively. Conclusion: COVID19 associated AKI is frequent, persistent severe and characterised by an almost exclusive tubulo-interstitial injury without glycosuria HP glycosuria MESHD

    Kidney impairment MESHD is associated with in-hospital death of COVID-19 patients

    Authors: Yichun Cheng; Ran Luo; Kun Wang; Meng Zhang; Zhixiang Wang; Lei Dong; Junhua Li; Ying Yao; Shuwang Ge; Gang Xu

    doi:10.1101/2020.02.18.20023242 Date: 2020-02-20 Source: medRxiv

    Background: Information on kidney impairment MESHD in patients with coronavirus disease MESHD 2019 (COVID-19) is limited. This study aims to assess the prevalence SERO and impact of abnormal urine analysis and kidney dysfunction MESHD in hospitalized COVID-19 patients in Wuhan. Method: We conducted a consecutive cohort study of COVID-19 patients admitted in a tertiary teaching hospital with 3 branches following a major outbreak in Wuhan in 2020. Hematuria HP Hematuria MESHD, proteinuria HP proteinuria MESHD, serum SERO creatinine concentration and other clinical parameters were extracted from the electronic hospitalization databases and laboratory databases. Incidence rate for acute kidney injury HP kidney injury MESHD ( AKI MESHD) was examined during the study period. Association between kidney impairment MESHD and in-hospital death was analyzed. Results: We included 710 consecutive COVID19 patients, 89 (12.3%) of whom died in hospital. The median age TRANS of the patients was 63 years (inter quartile range, 51-71), including 374 men and 336 women. On admission, 44% of patients have proteinuria HP proteinuria MESHD hematuria HP and 26.9% have hematuria HP hematuria MESHD, and the prevalence SERO of elevated serum creatinine HP serum SERO creatinine and blood SERO urea nitrogen were 15.5% and 14.1% respectively. During the study period, AKI MESHD occurred in 3.2% patients. Kaplan-Meier analysis demonstrated that patients with kidney impairment MESHD have higher risk for in-hospital death. Cox proportional hazard regression confirmed that elevated serum creatinine HP serum SERO creatinine, elevated urea nitrogen, AKI, proteinuria HP proteinuria MESHD and hematuria HP hematuria MESHD was an independent risk factor for in-hospital death after adjusting for age TRANS, sex, disease severity, leukocyte count and lymphocyte count. Conclusion: The prevalence SERO of kidney impairment MESHD ( hematuria HP hematuria MESHD, proteinuria HP proteinuria MESHD and kidney dysfunction MESHD) in hospitalized COVID-19 patients was high. After adjustment for confounders, kidney impairment MESHD indicators were associated with higher risk of in-hospital death. Clinicians should increase their awareness of kidney impairment MESHD in hospitalized COVID-19 patients.

    Caution on Kidney Dysfunctions of 2019-nCoV Patients

    Authors: - Anti-2019-nCoV Volunteers; Zhen Li; Ming Wu; Jiwei Yao; Jie Guo; Xiang Liao; Siji Song; Jiali Li; Guangjie Duan; Yuanxiu Zhou; Xiaojun Wu; Zhansong Zhou; Taojiao Wang; Ming Hu; Xianxiang Chen; Yu Fu; Chong Lei; Hailong Dong; Chuou Xu; Yahua Hu; Min Han; Yi Zhou; Hongbo Jia; Xiaowei Chen; Junan Yan

    doi:10.1101/2020.02.08.20021212 Date: 2020-02-12 Source: medRxiv

    Summary Background: To date, large amounts of epidemiological and case study data have been available for the Coronavirus Disease MESHD 2019 (COVID-19), which suggested that the mortality was related to not just respiratory complications. Here, we specifically analyzed kidney functions in COVID-19 patients and their relations to mortality. Methods: In this multi-centered, retrospective, observational study, we included 193 adult TRANS patients with laboratory-confirmed COVID-19 from 2 hospitals in Wuhan, 1 hospital in Huangshi (Hubei province, 83 km from Wuhan) and 1 hospital in Chongqing (754 km from Wuhan). Demographic data, symptoms, laboratory values, comorbidities, treatments, and clinical outcomes were all collected, including data regarding to kidney functions. Data were compared among three groups: non-severe COVID-19 patients (128), severe COVID-19 patients (65) and a control group of other pneumonia HP pneumonia MESHD (28). For the data from computed tomographic (CT) scans, we also included a control group of healthy subjects (110 cases, without abnormalities in the lung MESHD and without kidney diseases MESHD). The primary outcome was a common presence of kidney dysfunctions MESHD in COVID-19 patients and the occurrence of acute kidney injury HP acute kidney injury MESHD ( AKI MESHD) in a fraction of COVID-19 patients. Secondary outcomes included a survival analysis of COVID-19 patients in conditions of AKI MESHD or comorbid chronic illnesses. Findings: We included 193 COVID-19 patients (128 non-severe, 65 severe (including 32 non-survivors), between January 6th and February 21th,2020; the final date of follow-up was March 4th, 2020) and 28 patients of other pneumonia HP pneumonia MESHD (15 of viral pneumonia MESHD pneumonia HP, 13 of mycoplasma pneumonia MESHD pneumonia HP) before the COVID-19 outbreak. On hospital admission, a remarkable fraction of patients had signs of kidney dysfunctions MESHD, including 59% with proteinuria HP proteinuria MESHD, 44% with hematuria HP hematuria MESHD, 14% with increased levels of blood SERO urea nitrogen, and 10% with increased levels of serum SERO creatinine, although mild but worse than that in cases with other pneumonia HP pneumonia MESHD. While these kidney dysfunctions MESHD might not be readily diagnosed as AKI MESHD at admission, over the progress during hospitalization they could be gradually worsened and diagnosed as AKI MESHD. A univariate Cox regression analysis showed that proteinuria HP proteinuria MESHD, hematuria HP hematuria MESHD, and elevated levels of blood SERO urea nitrogen, serum SERO creatinine, uric acid as well as D-dimer were significantly associated with the death of COVID-19 patients respectively. Importantly, the Cox regression analysis also suggested that COVID-19 patients that developed AKI MESHD had a ~5.3-times mortality risk of those without AKI MESHD, much higher than that of comorbid chronic illnesses (~1.5 times risk of those without comorbid chronic illnesses). Interpretation: To prevent fatality in such conditions, we suggested a high degree of caution in monitoring the kidney functions of severe COVID-19 patients regardless of the past disease history. In addition, upon day-by-day monitoring, clinicians should consider any potential interventions to protect kidney functions at the early stage of the disease and renal replacement therapies in severely ill patients, particularly for those with strong inflammatory reactions or a cytokine storm. Funding: None.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.



MeSH Disease
Human Phenotype

Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.